MX2022014203A - Espaciadores de receptores de antígenos quiméricos (car). - Google Patents

Espaciadores de receptores de antígenos quiméricos (car).

Info

Publication number
MX2022014203A
MX2022014203A MX2022014203A MX2022014203A MX2022014203A MX 2022014203 A MX2022014203 A MX 2022014203A MX 2022014203 A MX2022014203 A MX 2022014203A MX 2022014203 A MX2022014203 A MX 2022014203A MX 2022014203 A MX2022014203 A MX 2022014203A
Authority
MX
Mexico
Prior art keywords
derived
spacers
fragments
cars
disclosed
Prior art date
Application number
MX2022014203A
Other languages
English (en)
Inventor
Spencer Park
Marc Joseph Lajoie
Scott Edward Boyken
Brian Douglas Weitzner
Yun Song
Original Assignee
Lyell Immunopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyell Immunopharma Inc filed Critical Lyell Immunopharma Inc
Publication of MX2022014203A publication Critical patent/MX2022014203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a receptores de antígenos quiméricos (CAR) que comprenden espaciadores derivados de inmunoglobulina (Ig), por ejemplo, regiones bisagra o bucle, fragmentos de estas o combinaciones de estas. El espaciador derivado de Ig otorga propiedades mejoradas a los CAR, por ejemplo, mayor liberación de citocinas con respecto a los CAR con espaciadores no derivados de regiones bisagra y fragmentos de estas, regiones de bucle de dominios constantes y fragmentos de estas, y combinaciones de estas. También se proporcionan células que expresan CAR que comprenden regiones espaciadoras derivadas de Ig y métodos para usar los CAR para tratar enfermedades o trastornos, por ejemplo, cáncer. Algunos de los espaciadores derivados de Ig descritos son fragmentos de, por ejemplo, IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4 o IgM. En algunos aspectos, los espaciadores derivados de Ig descritos derivan de inmunoglobulinas no humanas, por ejemplo, inmunoglobulinas de ratón tales como IgG2A. Otros espaciadores derivados de Ig descritos son construcciones modulares que comprenden varias bisagras de Ig concatenadas o fragmentos de estas.
MX2022014203A 2020-05-12 2021-05-12 Espaciadores de receptores de antígenos quiméricos (car). MX2022014203A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023751P 2020-05-12 2020-05-12
PCT/US2021/032098 WO2021231655A1 (en) 2020-05-12 2021-05-12 Chimeric antigen receptor spacers

Publications (1)

Publication Number Publication Date
MX2022014203A true MX2022014203A (es) 2023-02-22

Family

ID=76250478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014203A MX2022014203A (es) 2020-05-12 2021-05-12 Espaciadores de receptores de antígenos quiméricos (car).

Country Status (11)

Country Link
US (1) US20210380658A1 (es)
EP (1) EP4149968A1 (es)
JP (1) JP2023526234A (es)
KR (1) KR20230022411A (es)
CN (1) CN116096739A (es)
AU (1) AU2021270299A1 (es)
BR (1) BR112022022953A2 (es)
CA (1) CA3157427A1 (es)
IL (1) IL298114A (es)
MX (1) MX2022014203A (es)
WO (1) WO2021231655A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011673A (es) 2020-03-20 2022-12-13 Lyell Immunopharma Inc Nuevos marcadores de superficie celular recombinantes.
CN115724986B (zh) * 2022-07-11 2024-07-19 惠和生物技术(上海)有限公司 三特异性抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK0985039T3 (da) 1997-06-12 2008-06-09 Novartis Int Pharm Ltd Kunstige antistof-polypeptider
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
EP3824905A1 (en) * 2012-08-20 2021-05-26 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
GB201803079D0 (en) * 2018-02-26 2018-04-11 Autolus Ltd Cell
CN112236151A (zh) * 2018-03-14 2021-01-15 西雅图儿童医院（Dba西雅图儿童研究所） 用于肿瘤特异性T细胞免疫疗法的IL-13受体α2(IL13RA2)嵌合抗原受体
WO2019197676A1 (en) * 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
WO2019213184A1 (en) * 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
WO2019241557A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of California Fusion fragment chimeric antigen receptors and uses thereof
JP2022538397A (ja) * 2019-06-19 2022-09-02 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク キメラ抗原受容体設計で実施するためのウルトラモジュラー（ｕｌｔｒａｍｏｄｕｌａｒ） ＩｇＧ３ベーススペーサードメイン及び多機能部位

Also Published As

Publication number Publication date
US20210380658A1 (en) 2021-12-09
KR20230022411A (ko) 2023-02-15
BR112022022953A2 (pt) 2023-03-21
CA3157427A1 (en) 2021-11-18
IL298114A (en) 2023-01-01
AU2021270299A1 (en) 2022-12-15
CN116096739A (zh) 2023-05-09
EP4149968A1 (en) 2023-03-22
WO2021231655A1 (en) 2021-11-18
JP2023526234A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
MX2022014203A (es) Espaciadores de receptores de antígenos quiméricos (car).
Wang et al. IgG Fc engineering to modulate antibody effector functions
Liu et al. Fc-engineering for modulated effector functions—improving antibodies for cancer treatment
MY172472A (en) Mice that make heavy chain antibodies
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
LTPA2022520I1 (es)
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
RU2013152730A (ru) Антитела к ох-2/cd200 и их применение
WO2006133450A3 (en) Anti-cd19 antibody therapy for the transplantation
SI2699264T1 (en) Antibodies and other molecules that bind B7-H1 and PD-1
Stockmeyer et al. Mechanisms of G-CSF-or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
ATE342282T1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
SG153878A1 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
WO2006002438A3 (en) Human monoclonal antibodies to fc gamma receptor i (cd64)
ATE553131T1 (de) Humane monoklonale antikörper gegen dendritische zellen
CN105392878A (zh) 用于控制蛋白质中的岩藻糖基化水平的方法
Bournazos et al. Humanized mice to study FcγR function
Mary et al. Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain
Schofield et al. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
Suchanek et al. Novel strategies to target the humoral alloimmune response
US20180028633A1 (en) Chimeric antigen receptor combination therapy for treating tumors
Manzke et al. Locoregional treatment of low‐grade B‐cell lymphoma with CD3× CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation